Primary Progressive Multiple Sclerosis Under Anti-TNFα Treatment: A Case Report

Area of Science:

• Neuroimmunology
• Demyelinating Diseases
• Autoimmune Disorders

Background:

• Tumour necrosis factor α (TNFα) antagonists are widely used for autoimmune diseases.
• While generally safe, immune-mediated adverse events, including neurological complications like demyelination, are increasingly reported.
• Central nervous system demyelination is a rare but recognized complication of TNFα antagonist therapy.

Purpose of the Study:

• To report a rare case of multiple sclerosis (MS) developing during TNFα antagonist treatment.
• To discuss the potential etiopathogenesis of MS in the context of TNFα antagonism.
• To raise awareness of neurological adverse events associated with TNFα inhibitor therapy.

Main Methods:

• Case report of a 45-year-old female patient.
• Patient was undergoing treatment with adalimumab for nodular cystic acne.
• Diagnosis of primary progressive multiple sclerosis was supported by clinical presentation and magnetic resonance imaging (MRI) findings characteristic of demyelinating disease.

Main Results:

• The patient developed clinical signs and symptoms consistent with primary progressive multiple sclerosis.
• MRI revealed lesions typical of central nervous system demyelination.
• The onset of MS symptoms occurred during adalimumab therapy.

Conclusions:

• This case illustrates a rare instance of multiple sclerosis associated with TNFα antagonist (adalimumab) treatment.
• The findings underscore the importance of monitoring for neurological adverse events in patients receiving TNFα inhibitors.
• Further research into the complex interplay between TNFα inhibition and neuroinflammation is warranted.